Abstract
Malignant mesothelioma is a disease that is refractory to chemotherapy. Therefore, the objective of this multi-institutional, cooperative group Phase II trial was to determine the efficacy of dihydro-5-azacytidine (DHAC), a pyrimidine analogue, in the treatment of malignant mesothelioma. Forty-one patients with histologically confirmed malignant mesothelioma received 120-hour continuous infusions of DHAC (1,500 mg/m2/day every 21 days) until maximal response, intolerable toxicity, or disease progression. One patient had a complete response, two had objective partial responses, and four had regression of evaluable disease. The overall response rate was 17%. The one complete responder remains without disease progression at 6 years. Chest pain and nausea were the most common toxicities. Supraventricular tachycardia and pericardial effusion occurred in 20% and 15% of patients, respectively. In most patients, gastrointestinal effects were manageable. There was no significant hematologic toxicity. In malignant mesothelioma, a disease that is refractory to chemotherapy, dihydro-5-azacytidine has definite antitumor activity. Its modest hematologic toxicity profile favors its use in combination with other agents. Caution regarding cardi...Continue Reading
References
Jun 1, 1992·British Journal of Cancer·O P SolheimA E Stenwig
Apr 15, 1991·Cancer·C BoutinA Jehan
Jan 1, 1990·Cancer Chemotherapy and Pharmacology·N J VogelzangM R Green
Jan 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D RaghavanB McCaughan
Jan 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K AntmanJ Corson
Mar 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S AlbertsC A Van der Merwe
Jun 1, 1982·Annals of Internal Medicine·A P ChahinianE M Mandel
Nov 1, 1995·British Journal of Cancer·S H GoeyG Stoter
Jul 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N J VogelzangM R Green
Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A P ChahinianL Leone
Jun 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D J SugarbakerK H Antman
Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S T Ong, N J Vogelzang
Citations
Apr 27, 2007·Journal of Cellular Physiology·Luca SigalottiMichele Maio
May 14, 2011·Epigenetics : Official Journal of the DNA Methylation Society·Marika MatoušováHelena Mertlíková-Kaiserová
Aug 29, 2002·Cancer Investigation·Keith M Skubitz
Mar 1, 2003·British Journal of Cancer·S TomekC Manegold
Nov 28, 2008·Molecular Diagnosis & Therapy·Laurent GreillierAlexandre Passioukov
Jun 2, 2012·Future Medicinal Chemistry·Marcela Krečmerová, Miroslav Otmar
Mar 23, 2018·Cancers·Yoshitaka Sekido
Apr 18, 2013·Pharmacological Reviews·Detlev Boison
Jun 3, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Everett E VokesMark R Green
Mar 2, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Makoto TakenouchiKazunori Kato
Jan 1, 2021·Frontiers in Oncology·Yoshie YoshikawaTakashi Kijima
Nov 27, 2020·Therapeutic Advances in Medical Oncology·Haitang YangRen-Wang Peng
Apr 4, 2021·Journal of Clinical Medicine·Sara LettieriGiulia M Stella
Nov 7, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Goffin, E Eisenhauer
Jul 21, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Sandra Tomek, Christian Manegold
Jun 14, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Priya Kumar, Robert A Kratzke
Nov 5, 2003·Clinical Lung Cancer·Pasi A Janne
Feb 9, 2010·Chest·Spasenija SavicLukas Bubendorf
Feb 25, 2011·Cellular Signalling·Juan RenShi-Wen Jiang
May 31, 2011·Trends in Pharmacological Sciences·Roberto E Favoni, Tullio Florio